A 72-year-old woman with a history of chronic immunosuppression (post-renal transplant 15 years ago) presents with multiple erythematous, scaly papules and plaques on her forearms and face. Over the past 2 years, one lesion on her left cheek has become indurated, has developed central erosion, and measures 2.5 cm. Biopsy of the cheek lesion shows invasive nests of atypical squamous cells with keratinization and increased mitotic activity. Histologic grade is poorly differentiated. What is the most appropriate next step in management?

Explanation

## Management of High-Risk Squamous Cell Carcinoma ### Risk Stratification **Key Point:** This patient has **multiple high-risk features** that demand aggressive surgical management: | Risk Feature | Present in This Case | Impact | |--------------|----------------------|---------| | **Immunosuppression** | Yes (post-transplant) | Increased SCC incidence 40–250×; higher recurrence & metastasis | | **Tumor size** | 2.5 cm (>2 cm) | High-risk threshold | | **Location** | Face (cheek) | High-risk anatomic site | | **Histologic grade** | Poorly differentiated | Aggressive behavior, higher metastatic potential | | **Mitotic activity** | Increased | Indicator of poor prognosis | ### Treatment Algorithm for High-Risk SCC ```mermaid flowchart TD A[SCC Diagnosis Confirmed]:::outcome --> B{Risk Stratification}:::decision B -->|Low-risk: <2 cm, well-diff, non-facial| C[Standard excision 4-6 mm margins]:::action B -->|High-risk: >2 cm, poor-diff, facial, immunocompromised| D[Mohs Micrographic Surgery]:::action D --> E[Complete margin assessment in real-time]:::action E --> F{Margins Clear?}:::decision F -->|Yes| G[Staging imaging: CT head/neck, CXR]:::action F -->|No| H[Re-excision or adjuvant therapy]:::action G --> I{Lymph Node Status?}:::decision I -->|Negative| J[Adjuvant radiation if high-risk features]:::action I -->|Positive/Suspicious| K[Lymph node dissection + adjuvant chemoradiation]:::action ``` ### Mohs Micrographic Surgery (MMS) **High-Yield:** MMS is the gold standard for high-risk SCC because: 1. **Real-time histologic margin assessment** — 100% of surgical margins examined 2. **Tissue-sparing** — removes only affected tissue, preserves function and cosmesis 3. **Highest cure rate** — 95–99% for primary SCC; 90% for recurrent SCC 4. **Particularly valuable** on face, ears, lips, and in immunocompromised patients ### Adjuvant Radiation Therapy **Clinical Pearl:** Indications for adjuvant radiation after surgery: - Poorly differentiated histology - Perineural invasion - Depth >4 mm - Positive or close margins - Immunosuppression - Recurrent tumors This patient meets multiple criteria and should receive adjuvant radiation. ### Why Each Alternative Is Incorrect **Topical 5-FU** is appropriate for: - Actinic keratosis (field treatment) - Superficial SCC or carcinoma in situ **NOT** for invasive, poorly-differentiated SCC with depth and size >2 cm. **Cryotherapy** is used for: - Small, low-risk AK or early SCC - Not for invasive, high-grade lesions **Systemic chemotherapy** (cisplatin + 5-FU) is reserved for: - Metastatic SCC (Stage IV) - Unresectable disease - Palliative intent Not first-line for localized, resectable high-risk SCC. ### Prognosis & Follow-Up **Key Point:** Immunocompromised patients (transplant recipients) have: - 40–250× higher SCC incidence - Higher recurrence rates (10–20% vs. 3–5% in immunocompetent) - More aggressive tumors - Increased risk of metastasis **Follow-up protocol:** - Clinical examination every 3 months for first 2 years - Then every 6 months for life - Patient self-examination monthly - Consider dermatology surveillance for field cancerization (multiple AK/SCC lesions)